MA52920A - Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f - Google Patents

Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Info

Publication number
MA52920A
MA52920A MA052920A MA52920A MA52920A MA 52920 A MA52920 A MA 52920A MA 052920 A MA052920 A MA 052920A MA 52920 A MA52920 A MA 52920A MA 52920 A MA52920 A MA 52920A
Authority
MA
Morocco
Prior art keywords
pyridinoylpiperidine
compositions
methods relating
ht1f agonists
ht1f
Prior art date
Application number
MA052920A
Other languages
English (en)
Other versions
MA52920B1 (fr
Inventor
Brigida Allieri
Paul Fagan
Emma Sharp
Raymond D Skwierczynski
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52920(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of MA52920A publication Critical patent/MA52920A/fr
Publication of MA52920B1 publication Critical patent/MA52920B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA52920A 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f MA52920B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06
PCT/US2017/064652 WO2018106657A1 (fr) 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Publications (2)

Publication Number Publication Date
MA52920A true MA52920A (fr) 2021-04-28
MA52920B1 MA52920B1 (fr) 2021-11-30

Family

ID=60972336

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52920A MA52920B1 (fr) 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Country Status (38)

Country Link
US (1) US11053214B2 (fr)
EP (1) EP3551617B1 (fr)
JP (4) JP2020500936A (fr)
KR (4) KR20250070124A (fr)
CN (3) CN115385894A (fr)
AU (1) AU2017373784B2 (fr)
BR (1) BR112019010934A2 (fr)
CA (1) CA3043772C (fr)
CL (1) CL2019001426A1 (fr)
CO (1) CO2019005290A2 (fr)
CR (1) CR20190251A (fr)
CY (1) CY1124540T1 (fr)
DK (1) DK3551617T3 (fr)
DO (1) DOP2019000139A (fr)
EA (1) EA201991112A1 (fr)
EC (1) ECSP19040190A (fr)
ES (1) ES2889476T3 (fr)
HR (1) HRP20211557T1 (fr)
HU (1) HUE056820T2 (fr)
IL (1) IL266598B2 (fr)
JO (1) JOP20190129B1 (fr)
LT (1) LT3551617T (fr)
MA (1) MA52920B1 (fr)
MD (1) MD3551617T2 (fr)
MX (2) MX392547B (fr)
MY (1) MY196855A (fr)
NZ (1) NZ752906A (fr)
PE (2) PE20241297A1 (fr)
PH (1) PH12019501252B1 (fr)
PL (1) PL3551617T3 (fr)
PT (1) PT3551617T (fr)
RS (1) RS62415B1 (fr)
SI (1) SI3551617T1 (fr)
TN (1) TN2019000174A1 (fr)
TW (1) TWI671290B (fr)
UA (1) UA124433C2 (fr)
WO (1) WO2018106657A1 (fr)
ZA (1) ZA201903449B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010359A (es) 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
US12271057B1 (en) 2019-12-20 2025-04-08 The Uab Research Foundation Chromatic aberration tuning ophthalmic corrector lens methods
EP4333815A1 (fr) 2021-05-07 2024-03-13 Eli Lilly And Company Compositions à goût masqué d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyl)-pyridin-2-yl]-benzamide et comprimé à désintégration orale les comprenant
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
MX2011010359A (es) * 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
CN114213393A (zh) 2016-07-15 2022-03-22 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
KR20190075130A (ko) 2019-06-28
PH12019501252B1 (en) 2024-05-24
JP2020500936A (ja) 2020-01-16
CN115385894A (zh) 2022-11-25
EP3551617B1 (fr) 2021-08-11
JOP20190129A1 (ar) 2019-05-29
IL266598A (en) 2019-07-31
JP2023123678A (ja) 2023-09-05
CL2019001426A1 (es) 2019-10-11
JP2024178323A (ja) 2024-12-24
TWI671290B (zh) 2019-09-11
SI3551617T1 (sl) 2021-11-30
MX392547B (es) 2025-03-24
TN2019000174A1 (en) 2020-10-05
NZ752906A (en) 2021-07-30
JP2022000451A (ja) 2022-01-04
CO2019005290A2 (es) 2019-05-31
CA3043772C (fr) 2022-06-07
MY196855A (en) 2023-05-05
ECSP19040190A (es) 2019-08-30
UA124433C2 (uk) 2021-09-15
KR20230008257A (ko) 2023-01-13
IL266598B1 (en) 2024-01-01
CA3043772A1 (fr) 2018-06-14
PT3551617T (pt) 2021-10-04
CR20190251A (es) 2019-08-26
CN110291079A (zh) 2019-09-27
HRP20211557T1 (hr) 2022-01-07
ES2889476T3 (es) 2022-01-12
ZA201903449B (en) 2021-02-24
TW201833097A (zh) 2018-09-16
JP7561240B2 (ja) 2024-10-03
KR20210102497A (ko) 2021-08-19
BR112019010934A2 (pt) 2019-10-01
US20200087279A1 (en) 2020-03-19
PE20241297A1 (es) 2024-06-24
CY1124540T1 (el) 2022-07-22
MX388091B (es) 2025-03-19
RS62415B1 (sr) 2021-10-29
MD3551617T2 (ro) 2021-12-31
JP7818666B2 (ja) 2026-02-20
DK3551617T3 (da) 2021-09-13
MX2021014139A (es) 2022-05-24
KR20250070124A (ko) 2025-05-20
EP3551617A1 (fr) 2019-10-16
PH12019501252A1 (en) 2019-12-02
MX2019006520A (es) 2019-08-21
PL3551617T3 (pl) 2021-12-20
HUE056820T2 (hu) 2022-03-28
AU2017373784A1 (en) 2019-05-16
IL266598B2 (en) 2024-05-01
WO2018106657A1 (fr) 2018-06-14
DOP2019000139A (es) 2019-08-15
US11053214B2 (en) 2021-07-06
AU2017373784B2 (en) 2020-04-23
JOP20190129B1 (ar) 2023-03-28
LT3551617T (lt) 2021-10-11
CN115385893A (zh) 2022-11-25
MA52920B1 (fr) 2021-11-30
EA201991112A1 (ru) 2019-10-31
PE20191134A1 (es) 2019-09-02

Similar Documents

Publication Publication Date Title
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
EP3380602A4 (fr) Procédés et compositions se rapportant à des récepteurs antigéniques chimériques
EP3823673A4 (fr) Compositions anti-cd112r et procédés
EP3397261A4 (fr) Procédés et compositions se rapportant aux chondrisomes
EP3359523A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3373906A4 (fr) Compositions et procédés destinés à une application sur la peau
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3471745A4 (fr) Procédés et compositions pour réduire le stress oxydatif
MA45779A (fr) Polypeptides immunomdulateurs et compositions et procédés associés
EP3464376A4 (fr) Compositions et procédés se rapportant à des constructions fc génétiquement modifiées
EP3503879A4 (fr) Compositions et procédés associés
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
MA52920A (fr) Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3013957A4 (fr) Compositions et procédés de traitement d'échantillon
EP2971142A4 (fr) Compositions et procédés destinés à moduler l'expression de tau
PL3274469T3 (pl) Kompozycje i sposoby wykrywania zanieczyszczenia biologicznego
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
EP3439688A4 (fr) Compositions et procédés associés à des lymphocytes t polycytotoxiques
EP3373950A4 (fr) Procédés et compositions d'évaluation de spécificités d'anticorps
PT3261437T (pt) Compostos e composições fungicidas
EP3349788A4 (fr) Compositions antimalariques et procédés
EP3416483A4 (fr) Compositions de cryoprotection et procédés